This study is currently not recruiting participants.
A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
Not Recruiting
18 years - 65 years
All
Phase
N/A
Brief description of study.
The purpose of this study is to test the effectiveness of a new drug on atopic dermatitis.
Detailed description of study
The purpose of this study is to test the effectiveness of a new drug on atopic dermatitis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Dermatitis
Age:
18 years - 65 years
Gender: All
Updated on
20 Jun 2014.
Study ID: CIM003JG
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
